Related Experiment Video
Updated: Jun 12, 2025
Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
Is Canada Moving towards a More Agile Regulatory Approval and Reimbursement Process with a Shifting Role for
Catherine Y Lau1, Nigel S B Rawson2,3,4
1Independent Researcher, 158 Front Street E, Toronto, ON M5A 0K9, Canada.
Abstract:
Canada is known to have a complex pathway for new drug approval and reimbursement, resulting in delayed access for patients with serious and life-threatening diseases, such as cancer. Several recent publications from key stakeholders, including patients, physicians and policymakers, highlight patient helplessness, physician frustrations and policymakers entangled in a massive network of bureaucracy unable to make headway. Several quantitative and qualitative assessments using time from regulatory approvals to successful reimbursements confirm long review times and high rejection rates for oncology drugs, especially those receiving conditional approvals. A consensus forum of 18 Canadian oncology clinicians recently voiced frustration with the process and inability to deliver guideline-supported efficacious therapies to their patients. This manuscript compares data extracted from publicly available data sources from 2019 to June 2024 to previous publications. Methods: Public databases from Health Canada, the Canadian Agency for Drugs and Technologies in Health (CADTH), which is in the process of changing to Canada's Drug Agency, and the pan-Canadian Pharmaceutical Alliance (pCPA) were reviewed and the data collected were analyzed with descriptive statistics. Results: From the data, three trends emerge, (i) an increasing number of oncology drugs are receiving conditional approvals from Health Canada, (ii) the percentage of conditionally approved oncology drugs receiving positive reimbursement recommendations from CADTH is still low but appears to be improving, but delays in access are now contingent upon pCPA deciding whether to negotiate price and then the duration of any negotiation, and (iii) real-world evidence is no longer part of the decision-making for conditional approvals. A slight increase in the positive endorsement of RWE used to support CADTH recommendations was observed. Conclusions: The lack of timely access to oncology drugs hurts Canadian patients. While a small trend of improvement appears to be emerging, longer-term data collection is required to ensure sustained patient benefits.
Insights
Canadian patients face delays accessing new cancer drugs due to complex approval and reimbursement processes. While some improvements are noted, timely access remains a significant challenge requiring further data collection.
Area of Science:
- Health Policy
- Oncology Drug Access
- Pharmaceutical Reimbursement
Background:
- Canada's drug approval and reimbursement system presents complex challenges, leading to delayed patient access to critical oncology therapies.
- Stakeholder reports indicate patient helplessness and physician frustration with bureaucratic hurdles in drug access.
- Previous assessments confirm lengthy review times and high rejection rates for cancer drugs, particularly those with conditional approval.
Purpose of the Study:
- To analyze trends in oncology drug approval and reimbursement in Canada from 2019 to June 2024.
- To compare current data with previous publications on drug access timelines.
- To identify key factors contributing to delays in patient access to novel cancer treatments.
Main Methods:
- Review of publicly available data from Health Canada, Canadian Agency for Drugs and Technologies in Health (CADTH), and the pan-Canadian Pharmaceutical Alliance (pCPA).
- Descriptive statistical analysis of collected data.
- Comparison of current trends with historical data on drug approval and reimbursement.
Main Results:
- An increasing trend in conditional approvals for oncology drugs by Health Canada.
- A low but improving rate of positive reimbursement recommendations from CADTH for conditionally approved drugs.
- Access delays are now significantly influenced by the pan-Canadian Pharmaceutical Alliance's (pCPA) pricing negotiations and timelines; real-world evidence is less frequently used for initial conditional approvals.
Conclusions:
- Delayed access to oncology drugs negatively impacts Canadian patients.
- While minor improvements in the reimbursement process are emerging, sustained patient benefit requires longer-term data and consistent positive trends.
- Further monitoring is essential to ensure the evolving system effectively addresses patient needs for timely access to cancer therapies.
More Related Videos
Related Concept Videos
01:11Clinical Trials: Overview
01:25Drug Regulation
01:03Drug Control Governance: Regulatory Bodies and Their Impact
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:21Cancer Survival Analysis
01:19Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...